Gastrointestinal side effects of immune checkpoint inhibitors: new topic for gastrooncologists

Semra Paydas*
Cukurova University Faculty of Medicine Dept of Medical Oncology Adana, Turkey

Abstract

Immune checkpoint inhibitors (ICIs) are important novel drugs in cases with different types of cancers including malignant melanoma, non-small cell lung cancer, renal cell cancer, urothelial cancers, Hodgkin lymphoma, hepatocellular cancer, head and neck cancer, Merkel cell cancer and also mismatch repair-deficient solid tumors. Immune checkpoint blockade increases anti-tumor immunity by blocking intrinsic downregulators of immunity, such as cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death 1 (PD-1) or its ligand, programmed cell death ligand 1 (PD-L1). However these blockers have many immune-related side effects. Gastrointestinal tract and liver are affected from these drugs. Here these side effects and their management have been reviewed.

Core tip: Immune checkpoint inhibitors (ICIs) are important agents in cases with different types of cancers. Immune checkpoint blockade increases anti-tumor immunity by blocking intrinsic downregulators of immunity, such as cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death 1 (PD-1) or its ligand, programmed cell death ligand 1 (PD-L1). While these blockers have many immune-related side effects. Gastrointestinal tract and liver are affected from these drugs. Here these side effects and their management have been reviewed.

Introduction

Immune checkpoint inhibitors (ICIs) are important drugs in cases with different types of cancers including malignant melanoma, non-small cell lung cancer, renal cell cancer, urothelial cancers, Hodgkin lymphoma, hepatocellular cancer, head and neck cancer, Merkel cell cancer and also mismatch repair-deficient solid tumors. Immune checkpoint blockade increases antitumor immunity by blocking intrinsic downregulators of immunity, such as cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death 1 (PD-1) or its ligand, programmed cell death ligand 1 (PD-L1).

First monoclonal antibody showing impressive clinical activity is CTLA-4 inhibitor ipilimumab in malignant melanoma and then good results have been reported with PD-1/PD-L1 inhibitors including nivolumab, pembrolizumab, durvalumab, atezolizumab, avelumab etc. Although these drugs have important roles in augmenting T-cell specific and durable responses in clinical practice, they cause inflammatory side effects. Systemic and organ-specific side effects of ICIs are classified as immune related adverse events (irAEs) [1-3]. Although almost all the organs are injured by these side effects irAEs are seen most commonly in gastrointestinal (GI) tract, in the liver, endocrine glands, and skin. Management of irAEs require multidisciplinary collaboration between oncologists and gastroenterologist: gastroenteroncologist will be an important term in next years due to the wide spectrum of these side effects. Figure 1 shows side effects of the ICIs [2]. CTLA-4 inhibits immune response by attenuating T-cell activation at a proximal step while PD-1 inhibits T cells at later stages of the immune response in peripheral tissues. For this reason toxicity profile of these blockers are different. Many cytokines have important roles in the pathophysiology of irAEs [2,4-8].

Here gastrointestinal, hepatic and pancreatic irAEs and management of toxicity of monoclonal antibodies targeting CTLA-4 and PD-1/PD-L1 system will be discussed. Ipilimumab is the most frequently used anti-CTLA-4 monoclonal antibody while nivolumab, pembrolizumab, atezolizumab are the most frequently used monoclonal antibodies targeting PD-1/PD-L1 system [9]. An important strategy is to combine these two antibody systems with higher incidence and changing toxicity profile. Liver and GI toxicities are seen in 14th and 26th weeks of the nivolumab therapy while these toxicities are seen in 7th week of the ipilimumab-nivolumab combinations [10]. Some of the irAEs can be severe enough and requiring discontinuation or interruption of these drugs. Early diagnosis and appropriate treatment of irAEs are important to reduce morbidity and also mortality.

Time, cumulative toxicity and genetic factors for immune-related adverse events

irAEs generally develop within the first weeks but may be seen several months after ICI treatment and even can be seen after discontinuation of the therapy. However, there is no clear evidence of cumulative toxicity or safety in long term users of PD-1/PD-L1 inhibitors [11]. There is evidence of some genetic factors including microbiologic composition of patients gastrointestinal flora related to the development of irAEs [12,13]. Figure 2 shows the timing the occurrence of irAEs [14].

*Correspondence to: Semra Paydas MD Prof, Cukurova University Faculty of Medicine Dept of Medical Oncology Adana, Turkey, E-mail: sepay@cu.edu.tr

Key words: immune checkpoint blocker, PD-1, PD-L1, CTLA-4, immunotherapy, adverse effects, hepatotoxicity, GI toxicity

Received: May 19, 2019; Accepted: June 10, 2019; Published: June 13, 2019
Immune related hepatotoxicity

Definition

Liver is a key target organ for autoimmune toxicity, named as immune-related hepatotoxicity or immune-mediated hepatitis [3].

Incidence

Hepatitis occurs in 1-10% of the cases treated by single agent ipilimumab, nivolumab or pembrolizumab and 1-2% of these are grade III [15,16]. Although clinically significant hepatotoxicity is less common than other organ toxicities, fatal immune-related liver injury has been reported in some clinical studies and especially in post-marketing setting. For this reason early diagnosis and appropriate management are critical points [17]. Hepatitis occurs generally after 8-12 weeks of the initiation of ICI therapy but may be seen within 8 days or 21 months after therapy [7]. Incidence and severity of ICI-related hepatic toxicity has been shown in Table 1 [17].

Elevated AST and ALT levels have been reported in 2-5% of the cases in a meta-analysis covering 46 clinical trials of anti-PD-1 agents (nivolumab, pembrolizumab, atezolizumab, durvalumab, avelumab, BMS-936559). Increased bilirubin levels have been reported in 1-2% of the cases. Higher incidence of toxicity has been reported in patients treated with combinations in up to 30% of the cases and ≥ grade III toxicity has been reported in 6-19% of these cases [7,18-23].

Onset, severity and predisposing/risk factors for liver toxicity

Immune mediated hepatitis ranges in severity between mild-moderate to life-threatening and simulate idiopathic auto-immune hepatitis. ICI-induced liver injury is depend on:

1- Type of molecule: CTLA-4 or PD-1/PD-L1,
2- ICI-dose level: In cases treated by ipilimumab, the rates of grade III-IV irAEs are seen in 0%, 7% and 25% of the cases treated with 0.3mg/kg, 3mg/kg and 10mg/kg; respectively [24],
3- CTLA-4, PD-1/PD-L1 combinations cause more toxicity as compared with single agent using [25,26],
4- Underlying subclinical form of idiopathic autoimmune hepatitis may be predictive for more severe autoimmune liver injury [27],
5- Chronic liver infection is an important predictive factor for higher grade ICI-induced liver injury,
6- Liver parenchymal disease due to underlying tumor is an important factor for liver injury [3].

The most important factors in the management of liver toxicity are assessment the cause of liver injury, optimal management and monitoring of ICI related toxicity, critical decision to continue or to discontinue ICI treatment and also the use of steroidal or immunosuppressive drugs. For these reasons regular monitoring of liver function tests during and also after treatment with ICIs is critically important to prevent risk of serious adverse events. CTLA-4 blocker ipilimumab causes more liver toxicity than PD-1 blockers and patients treated by ipilimumab must be monitored more closely [3].

Patients with chronic viral hepatitis or human immunodeficiency virus (HIV) infection have generally been excluded from trials with immune checkpoint blockade. However, similar side effects have been reported in cases with hepatocellular cancer treated by nivolumab in a prospective study in patients with or without hepatitis B or hepatitis C related hepatitis [28].

Higher incidence and grade III-IV hepatotoxicity have been found in cases with hepatocellular cancer treated by nivolumab. More severe hepatotoxicity is attributed to additive effects of tissue autoantigen release due to tumor infiltration and also viral damage in conjunction

Table 1. Hepatotoxicity associated with ICI [17]

<table>
<thead>
<tr>
<th>Mo Ab</th>
<th>Target</th>
<th>Incidence (%) (fatal*)</th>
<th>Median time to onset (month)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ipilimumab</td>
<td>CTLA-4</td>
<td>4-11, (0.2*)</td>
<td>1.4-2</td>
</tr>
<tr>
<td>Pembrolizum</td>
<td></td>
<td>0.7</td>
<td>1.3</td>
</tr>
<tr>
<td>Nivolumab</td>
<td>PD-1</td>
<td>1.8 (1.3 with ipilimumab combination)</td>
<td>3.3 (2.1 with ipilimumab combination)</td>
</tr>
<tr>
<td>Atezolizumab</td>
<td></td>
<td>0.9-1.3, (0.1*)</td>
<td>0.9-1.1</td>
</tr>
<tr>
<td>Avelumab</td>
<td>PD-L1</td>
<td>0.9, (0.1*)</td>
<td>3.2</td>
</tr>
<tr>
<td>Durvalumab</td>
<td></td>
<td>1.1, (0.1*)</td>
<td>1.7</td>
</tr>
</tbody>
</table>
with ICI-induced the autoreactive T cell activity. Grade III-IV ALT, AST and bilirubin increases have been found in 18%, 11% and 7%; respectively. Systemic steroids have been found to be necessary in only 5% of the cases [29].

Clinical presentation and diagnosis of liver toxicity

Patients are generally asymptomatic but some patients have fever, fatigue or jaundice. Fulminant hepatitis has been reported [29]. Serum transaminase and bilirubin levels must be monitored in all cycles in cases treated by ICI [3,7]. Diagnostic evaluation should rule out other etiologic factors [7]. Hepatotoxicity associated with ICIs may be in hepatocellular or cholestatic pattern and variable from mild abnormal laboratory findings to acute liver failure [30]. Typically hepatic injury is seen 1-3 months after ICI treatment but may be seen after longer period of treatment and even after discontinuation of the drug [3].

Imaging studies are not sensitive or specific for ICI-induced hepatotoxicity, but bile duct obstruction due to cholelithiasis, liver metastatic disease and vascular obstruction must be ruled out with imaging modalities [7]. Radiologic findings are normal in mild/ moderate cases. Periportal lymphadenopathy, periportal edema and hepatomegaly have been reported in cases with severe hepatotoxicity [29,30]. Concomitant drug using, alcohol, underlying disease causing hepatic dysfunction, infections especially viral infections must be considered and evaluated in cases developing hepatic dysfunction. Liver biopsy is necessary in cases with severe hepatic toxicity [31]. The most commonly seen hepatic dysfunction is lobular hepatitis and most commonly zone 3 is affected and this entity mimics autoimmune hepatitis [3,29,32].

Histopathologic findings Sinusoidal histiocytosis and central vein endotheilitis suggest ICI related inflammation. Portal tract inflammation and cholangitis may be seen and this may mimic non alcoholic steatohepatitis [17]. Portal and peri-portal inflammation and hepatocellular necrosis with infiltrating lymphocytes, plasma cells and eosinophils have been reported in 5 cases treated by ipilimumab with severe hepatic toxicity [33]. Panlobular hepatitis or bile duct injury have been reported in cases treated by ipilimumab but these are not specific for ICI related hepatotoxicity [33,34].

Recent studies show higher clinical activity in cases treated by CTLA- 4 and PD-1 combinations and ICIs and tyrosine kinase inhibitors with more toxicity especially irAEs. Higher ipilimumab dosing schedules cause more toxicity [3]. Table 2 shows the onset, incidence, grading and management of hepatotoxicity in cases treated by ICIs.

Summary of management

Routine clinical and laboratory assessments are critical for early detection and mitigation of ICI-induced hepatotoxicity. US FDA recommend monitoring laboratory tests including AST, ALT, bilirubin and clinical signs and symptoms before each dose, at periodic intervals and after discontinuation of treatment, and also when clinically indicated [35].

Corticosteroids are recommended in cases developing ≥ grade II toxicity. Persistent grade II elevations lasting more than 1-2 weeks require 1mg/Kg methylprednisolone or equivalent corticosteroid. However other causes of hepatic dysfunction must be ruled out before steroid therapy. Hepatitis generally responds to corticosteroids within 8 weeks but relapses are frequent when tapered this drug [36]. ICI may be re-started in case of improvement of liver function tests. Corticosteroid dose must be increased to 2mg/Kg if liver function tests do not improve or worsen. If there is no improvement in liver tests in cases treated by higher doses of steroid and also in the presence of ≥ grade III toxicity ICI must be stopped permanently. Transaminases and bilirubin levels must be monitored twice weekly. If there is no response to 2mg/ Kg steroid within 2-3 days mycophenolate mofetil must be added at 1000mg twice daily. The efficacy of N-acetylcyisteine, ursodeoxycholic acid or budesonide on the rapid normalization of liver function tests are not clear [37].

Liver biopsy is recommended in cases refractory to steroid and mycophenolate mofetil [3,38]. Infliximab is not used in the therapy of ICI-related hepatitis due to the risk of hepatotoxicity of tumor necrosis factor alpha inhibitors [7,17,39]. Anti-thymocyte globulin (ATG) may be used for ipilimumab related hepatic toxicity refractory to steroid and mycophenolate mofetil treatment. Tacrolimus is a third line choice as immunosuppressive drug. Hepatitis resolves within 4-6 weeks with appropriate treatment. If there is no improvement other contributing

<table>
<thead>
<tr>
<th>Table 2. Management ICI related hepatotoxicity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatotoxicity</td>
</tr>
<tr>
<td>----------------</td>
</tr>
<tr>
<td>Grade I</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Grade II</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Grade III</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Grade IV</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Rule out</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>*viral etiology including Hepatitis A,B,C serology, hepatitis E PCR</td>
</tr>
<tr>
<td></td>
<td>*disease related hepatic dysfunction, other drug-induced transaminase elevations including statins, antibiotics, alcohol,</td>
</tr>
<tr>
<td></td>
<td>*limit/discontinue probable hepatotoxic medications</td>
</tr>
<tr>
<td></td>
<td>*anti-ANA/LKM/SLA, LP, ICI, iron studies</td>
</tr>
<tr>
<td></td>
<td>* Imaging for metastases or clot</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Steroid dosage</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>G2 once G1: wean over 2 weeks, re-escalate if worsens, treatment may be resumed once prednisolone ≤10mg</td>
<td></td>
</tr>
<tr>
<td>G3/4: once improved to G2, can change to oral prednisolone and wean over 4 weeks; for G3 rechallenge only at consultant discretion</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Worsening despite steroids: if on oral change to IV (methyl)prednisolone</td>
</tr>
<tr>
<td></td>
<td>If on IV add MMF 500-1000 mg bd</td>
</tr>
<tr>
<td></td>
<td>If worsen on MMF, consider addition of tacrolimus</td>
</tr>
<tr>
<td></td>
<td>Consider ATG in steroid-MMF refractory (case report ESMO 31)</td>
</tr>
</tbody>
</table>

| Abbreviations: ALT: alanine transaminase; AST: aspartate transaminase; ANA: antinuclear antibodies; bd: twice daily; C: immune-checkpoint inhibitor; INR: international normalised ratio; IV: intra venous; ICI: lung clearance index; LFT: liver function test; LKM: liver kidney microsomal; MMF: mycophenolate mofetil; PCR: polymerase chain reaction; SLA/LP: soluble liver antigen/liver-pancreas antibody; SMA: smooth muscle autoantibody; ULN: upper limits of normal; US: ultrasound |

Note: This table has been modified from NCCN and ESMO guidelines
factors must be considered and diagnostic procedures must be repeated carefully. Hepatotoxic drugs, herbal medications and also CMV reactivation must be considered carefully.

**Gastrointestinal tract toxicity**

**Definition**

The term colitis defines abdominal pain or endoscopic/radiologic evidence of colonic inflammation [7].

**Incidence**

GI tract toxicity is the most frequently irAE in patients treated by anti-CTLA-4 antibody causing to discontinuation of this drug [7,40]. Diarrhea occurs in 27-54% of patients treated with anti-CTLA-4 monoclonal antibody. About one third of the cases have diarrhea and 8-22% of the cases have colitis [20,21,41]. Colon perforation has been reported in 1-1.5% in cases treated for melanoma and 6.6% of the cases treated for renal cell cancer related to ipilimumab-induced enterocolitis [41-44]. CTLA-4-induced enterocolitis risk has been found to be higher in cases receiving non-steroidal anti-inflammatory drugs [45]. There is limited data about the immune-related colitis in patients with underlying ulcerative colitis or Chron's disease; in a small study ipilimumab-induced colitis or disease relapse has been reported in 2 out of 6 cases [46].

Diarrhea and colitis incidence in cases treated by PD-1/PD-L1 blockers are lower than ipilimumab treated cases: 11-19% and 1-4%; respectively and grade III-IV toxicity is seen in 1-3% of the cases. However diarrhea and colitis incidence are highest in cases treated by CTLA-4 and PD-1/PD-L1 blocker combinations and up to 45% and 9-11% of these are ≥ grade III [22,23,36,47-49].

**Pathogenesis of ICI related GI toxicity**

Immune-related diarrhea associated with ICI treatments is the result of underlying colonic inflammation. In two retrospective studies, it has been shown that patients with a predominance of bacteria from the Bacteroidetes phylum had reduced rates of ipilimumab-induced colitis but underlying mechanism is not known. We need additional research to understand the mechanism of this microbial pattern and also to determine the role of manipulation of the microbiota with dietary intervention or use of probiotics or antibiotics in reducing the risk of colitis or other immune related adverse events in cases treated by ICI. On the other hand immunosuppression for the treatment of irAEs may increase the risk of opportunistic infections such as Aspergillus fumigatus pneumonia, cytomegalovirus hepatitis, and pneumocystis pneumonia [49].

**Clinical presentation and diagnosis**

**Gastrointestinal toxicity of anti-CTLA-4 antibodies:** Most common symptom of anti-CTLA-4-induced enterocolitis is diarrhea and is seen in up to 92% of patients. Other symptoms are vomiting, abdominal pain, hematochezia, weight loss and fever. About one-third of the patients have concomitant enteritis and colitis but diarrhea may be related due to enteritis alone in some cases [50]. There is urgency but there is no blood in stool samples. Nausea, vomiting, early satiety, bloating may be seen in cases with upper GI involvement. Oral ulcers and anal lesions such as fistulas, abscesses, fissures have been reported. Extra-intestinal manifestations of enterocolitis are arthralgia, endocrine disorders, skin disorders, hepatitis, nephritis and pancreatitis. Diarrhea appears usually in 6-8 weeks after initiation of treatment [22,51]. Half life of ipilimumab is 2 weeks but biological effect may persist for longer time after drug clearance. For this reason time of onset of GI toxicity is not clear. GI symptoms may occur during 1-10 infusions of anti-CTLA-4. Enterocolitis may occur several months after the last dose of ipilimumab and must be considered in cases not actively receiving this antibody [41].

**Laboratory findings:** Abnormal laboratory findings are anemia, high CRP and hypoalbuminemia. Fecal calprotectin has been found to be increased. Stool cultures for bacterial, parasitic and viral pathogens including Salmonella, Shigella, Campylobacter, Yersinia, Vibrio, Aeromonas, Clostridium difficile, rotavirus, norovirus, Escherichia coli O157:H7/shiga toxin, Cryptosporidium, Giardia must be done. Anti-neutrophil cytoplasmic antibodies have been found in the minority of the cases. Underlying infection must be ruled out in all cases with GI problems [7,52-56].

**Imaging:** Abdominal imaging is not necessary in grade I diarrhea but abdominal CT is useful in cases with abdominal pain and ≥ grade II diarrhea. CT findings are non specific but are useful to rule out some complications including bowel perforation, abscess, toxic megacolon [57]. Mesenteric vessel engorgement, marked thickening of bowel wall, mucosal hyperenhancement and fluid-filled colon are the most commonly detected findings in abdominal CT in cases with ICI related colitis. There are 3 patterns of colonic inflammation:

- **a-Diffuse colitis pattern of colonic wall thickening,**
- **b-Segmental colitis associated with diverticulosis,**
- **c-Isolated rectosigmoid colitis without diverticulosis** [58].

Endoscopy must be done in cases with bloody diarrhea and persistent and/or ≥ grade II diarrhea to confirm the ICI related GI involvement and also to exclude other etiologic factors. Flexible sigmoidoscopy and biopsies of the left colon can be diagnostic in approximately 95% of cases with ipilimumab-induced colitis. Ipilimumab-induced colitis generally shows continuous pattern for colonic inflammation with mucosal edema, erythema and diffuse and shallow ulcers but these are no specific for ICI related colitis [59]. On the other hand it is unclear whether sigmoidoscopy is sufficient in cases with PD-1/ PD-L1 inhibitor toxicity [50]. Small intestinal and colonic inflammation with PD-1/PD-L1 blockers are seen less prominent by endoscopy. Histopathologic features associated with PD-1/PD-L1 blockers are:

- **a-Active colitis with neutrophilic inflammation,**
- **b-Increased intra-epithelial lymphocytes, and increased numbers of apoptotic crypt epithelial cells,**
- **c-Rare granuloma formation,**
- **d- Chronicity findings are limited or absent,**
- **e-Lymphocytic colitis may be seen in some patients** [59,60].

Prediction of ipilimumab-related colitis: There is no specific biomarker but baseline microbiota composition may predictive for this entity. Increase in bacterium phylum species at baseline has been found to be related with the low risk of colitis while Faecalibacterium prausnitzii and Gemmier formicilis have been found to be related with the high risk of colitis [61,62].

**Gastrointestinal toxicity associated with anti-PD-1 antibodies:** There is limited data about this matter, irAEs are seen less frequently in cases treated by PD-1 blockers as compared with ipilimumab. Grade ≥ III toxicity is seen in 1-2% of the cases [23,63]. The most commonly
reported side effects are diarrhea, nausea, vomiting and abdominal pain and median time to onset of GI toxicity is 3 months. Endoscopic findings are variable from normal mucosa to signs of inflammation including mild erythema, mucosal friability or ulceration. Histologic findings are expansion at lamina propria, villus blunting, intra-epithelial neutrophils and increased crypt/gland apoptosis but intra-epithelial lymphocytes are seen less likely [64].

It has been reported 4 patterns associated with anti-PD-1 associated GI toxicity:

1. Acute colitis similar to colitis induced by anti-CTLA-4 antibody,
2. Microscopic colitis,
3. Upper GI involvement,
4. Pseudo-obstruction

GI toxicity associated with PD-1 blockers are sensitive to corticosteroid with 87.5% response rate [65].

Gastrointestinal toxicity of combined anti-CTLA-4 and anti-PD-1 antibodies: Data about combined using is relatively limited. Diarrhea and colitis appear earlier, more frequently and with higher grade toxicities [23,66,67]. Pancreatitis and small bowel enteritis have been reported and requires discontinuation of treatment. Severity of ICI-related GI tract toxicity and diagnostic tools have been shown in Table 3.

Diffential diagnosis in cases with ICI treated cases with GI symptoms

Tumor related signs and symptoms and GI infections are the main diagnostic problems in cases with ipilimumab-induced enteropathy. Stool analyses for bacterial enteropathogens and Clostridium difficile toxin must be evaluated in all cases receiving ipilimumab and severe diarrhea. CMV reactivation may be seen in these cases and must be considered in all cases [68].

Endoscopic lesions are erythema, loss of vascular pattern, erosions and ulcerations. Most of the involved sites of the GI tract are sigmoid colon and rectum; flexible sigmoidoscopy is sufficient in some cases, however colonic lesions are more extensive and may extend proximal in two thirds of the cases. Patchy discontinuous endoscopic lesions are detected in half of the cases. Diagnosis must be confirmed by biopsies done by sigmoidoscopy and/or colonoscopy. Histopathological findings are characterized by diffuse or patchy infiltration with neutrophils, eosinophils suggesting acute colitis. These findings are different from the lesions detected in chronic inflammatory bowel diseases but in some cases granulomas, basal plasmacytosis and crypt abnormalities (atrophy, distortion, branching, budding) mimicking inflammatory bowel disease may be seen. Upper GI signs and symptoms such as dysphagia, epigastric pain and endoscopically detected oesophageal ulcerations, gastritis and duodenitis have been reported. Chronic, mild, patchy inflammation in the stomach and duodenum have been reported in half of the cases with anti-CTLA-4-induced enterocolitis. Histopathologically crypt distortion, focal or heterogenous villus shortening, increase in eosinophils and mononuclear inflammation are seen in the lamina propria [7,17].

Management

Oral hydration is sufficient in cases with mild diarrhea. Dietary recommendations are not clear enough: banana, applesauce, toast diet, boiled vegetables, starchy cereals, crackers and soup may be useful. However it must be avoided from dietary supplements with high osmolality, foods with high fat and dairy due to the possibility of secondary lactase insufficiency in cases with small intestinal mucosal damage [7]. Anti-diarrheal drugs and electrolyte supplementation are sufficient in cases with mild diarrhea and anti-CTLA-4 treatment can be continued in these cases [41]. Loperamide should be used at low doses and only in patients with grade 1 diarrhea [17]. Corticosteroids should be used in cases with mild symptoms: grade 1 diarrhea/colitis persisting more than 2 weeks or ≥ grade II diarrhea with without infectious etiology. Budesonide 9mg daily at least 4 weeks is used in cases with grade 1 diarrhea/colitis persisting for more than 2 weeks and then tapered by 3 mg increments for a total of 4-6 weeks. Budesonide has been used to prevent occurrence of anti-CTLA-4-induced enterocolitis in 2 randomised trials but it has not been found to be useful [17,69].

Colonic perforation may be seen and subtotal colectomy and ileostomy or sigmiodostomy must be done in these cases due to severe inflammation of the remaining colon in the postoperative phase [45].

Prednisone 1 mg/kg daily can be given to patients with persistent grade 1 diarrhea and not responding to budesonide or patients with grade II diarrhea/colitis for more than 3 days. In patients responding, prednisone is gradually tapered by 5 to 10 mg weekly, and prednisone is discontinued over 4 to 6 weeks. Patients with symptoms associated with severe enterocolitis (≥ grade III diarrhea/colitis) must be hospitalized and anti-CTLA-4 therapy must be stopped. Intravenous fluids, anti-diarrheal drugs and electrolyte supplementation are recommended. The choice of anti-diarrheal drugs is based on the severity of the symptoms. Loperamide should be used at low doses for patients with grade I diarrhea/colitis persisting for more than 3 days. In patients responding, loperamide is gradually tapered by 1 to 2 mg weekly, and loperamide is discontinued over 4 to 6 weeks. Patients with symptoms associated with severe enterocolitis (≥ grade III diarrhea/colitis) must be hospitalized and anti-CTLA-4 therapy must be stopped.

Table 3. Diagnostic tools to evaluate the gastrointestinal toxicity associated with immune checkpoint inhibitors

<table>
<thead>
<tr>
<th>Diagnostic tool</th>
<th>Grade of toxicity</th>
<th>Which test</th>
</tr>
</thead>
<tbody>
<tr>
<td>Laboratory studies</td>
<td>Grade I-IV diarrhea without risk factors</td>
<td>Bacterial cultures in stool samples</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Salmonella, shigella, Campylobacterenteritis,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ecoli 0157:H7/shiga toxin</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Stool lactoferrin C difficile</td>
</tr>
<tr>
<td></td>
<td>Grade I-IV diarrhea with risk factors (travelers’ diarrhea, seafood or shellfish exposure)</td>
<td>Vibrio</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Aeromonas</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Listeria, Yersinia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cryptosporidium stool antigen ova and parasites</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Giardia stool antigen</td>
</tr>
<tr>
<td>Endoscopy</td>
<td>Grade II-IV diarrhea</td>
<td>Flexible sigmoidoscopy or colonoscopy</td>
</tr>
<tr>
<td>Imaging</td>
<td>Grade II-IV diarrhea and abdominal pain</td>
<td>Upper endoscopy (in patients with upper GI symptoms)</td>
</tr>
<tr>
<td></td>
<td>Grade III-IV diarrhea</td>
<td>Abdominal CT scan</td>
</tr>
</tbody>
</table>

Note: This table has been modified from NCCN and ESMO guidelines.
supplementation of electrolytes, and intravenous steroids: 1–2 mg/kg per day of methylprednisolone are important in the management of these cases. In patients responding to methylprednisolone an equivalent dose of oral prednisone can be used. The duration of steroid in these cases is not clear but it is advised to discontinue within 6 to 8 weeks or 8-12 weeks [7,41]. Steroid dose may be increased if patient does not respond to IV steroids within 3–5 days or showing relapse while receiving steroid; those patients must be defined as steroid refractory and may be treated with tumor necrosis factor-alpha inhibitor infliximab (5–10 mg/kg). Mycophenolate mofetil is an alternative if infliximab cannot be used [7,38,40,42,45].

Vedolizumab is a humanized gut-specific monoclonal antibody targeting integrin α4β7 may be an alternative to infliximab in cases with steroid-refractory and/or dependent enterocolitis. It has been found to be useful in 6 of 7 cases steroid-dependent or steroid-refractory ipilimumab-induced enterocolitis. This finding suggests the vedolizumab as potential choice to infliximab but additional evidence is necessary for the efficacy of this drug [2,17,70,71].

Elevated levels of interleukin-17 have been reported in patients with ipilimumab-induced colitis and interleukin-17 elevations have been observed in preclinical models of colitis [71-73]. These findings suggest the using interleukin-17 blockade as a strategy for treating colitis induced by ICI. However, there is also a theoretical risk of decrease of antitumor effects of ICI [58].

Follow up and long term implications: It has been shown many times that ipilimumab-induced enterocolitis is associated with better response to underlying malignancy and survival. The use of corticosteroids or infliximab are not associated with response to ipilimumab [40,42,74]. Histologic or endoscopic inflammation may be seen after several months of enterocolitis and it is not clear whether these changes evolve into chronic inflammatory bowel disease. Repeated administration of ipilimumab in cases developing enterocolitis may cause relapse [45]. In clinical practice nivolumab and ipilimumab may be used sequentially and the development of enterocolitis with first cause relapse [45]. In clinical practice nivolumab and ipilimumab may be used sequentially and the development of enterocolitis with first cause relapse [45]. In clinical practice nivolumab and ipilimumab may be used sequentially and the development of enterocolitis with first cause relapse [45]. In clinical practice nivolumab and ipilimumab may be used sequentially and the development of enterocolitis with first cause relapse [45]. In clinical practice nivolumab and ipilimumab may be used sequentially and the development of enterocolitis with first cause relapse [45]. In clinical practice nivolumab and ipilimumab may be used sequentially and the development of enterocolitis with first cause relapse [45].

Table 4. Management of colitis and diarrhea associated with ICI

<table>
<thead>
<tr>
<th>Symptom grade</th>
<th>Symptom evaluation</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild: grade I</td>
<td>&lt;3 liquid stools/daily, feeding well,</td>
<td>If grade I persists &gt;14 days prednisolone 0.5-1 mg/kg/day (non-enteric coated) or budesonide 9 mg bd</td>
</tr>
<tr>
<td>Moderate: grade II</td>
<td>4-6 liquid stools daily, nausea or nocturnal episodes</td>
<td>If possible, outpatient management IV methylprednisolone 1 mg/kg/day No response in 2-3 days: increase dose 2 mg/kg/day Consider infliximab If infliximab-refractory, consider vedolizumab</td>
</tr>
<tr>
<td>Severe Grade III-IV</td>
<td>&gt;4-6 liquid stools daily or if episodes within 1 h of eating</td>
<td>ICI can be continued, symptomatic management, Oral fluids, loperamide, to avoid from high fibre/lactose diet</td>
</tr>
</tbody>
</table>

Management

The clinical significance of pancreatic enzyme elevations without the signs of acute pancreatitis is not clear in cases treated by ICIs. Subclinical pancreatic inflammation may be associated with asymptomatic pancreatic exocrine insufficiency and diabetes but does not require immuno-suppressive treatment, these cases may be monitored by abdominal CT or MRI. For this reason routine assessment of pancreatic enzymes in asymptomatic patients are not necessary [78-81].

First step is the diagnosis of acute pancreatitis and must be suspected in cases with acute onset and persistent epigastric pain. Diagnosis of acute pancreatitis must be confirmed by acute onset

Table 4 shows the management of colitis and diarrhea associated with ICI. The management of colitis and diarrhea associated with ICI shows a significant reduction in the incidence and severity of irAEs. The significance of this finding is supported by the fact that irAEs have not been found to be increased in a retrospective analysis covering 576 cases which 312 of them treated with ipilimumab [77].

Table 4 shows the management of colitis and diarrhea associated with ICI. The management of colitis and diarrhea associated with ICI shows a significant reduction in the incidence and severity of irAEs. The significance of this finding is supported by the fact that irAEs have not been found to be increased in a retrospective analysis covering 576 cases which 312 of them treated with ipilimumab [77].

Table 4 shows the management of colitis and diarrhea associated with ICI. The management of colitis and diarrhea associated with ICI shows a significant reduction in the incidence and severity of irAEs. The significance of this finding is supported by the fact that irAEs have not been found to be increased in a retrospective analysis covering 576 cases which 312 of them treated with ipilimumab [77].

Table 4 shows the management of colitis and diarrhea associated with ICI. The management of colitis and diarrhea associated with ICI shows a significant reduction in the incidence and severity of irAEs. The significance of this finding is supported by the fact that irAEs have not been found to be increased in a retrospective analysis covering 576 cases which 312 of them treated with ipilimumab [77].
Table 5. Pancreatic adverse events; symptom evaluations, assessments and management

<table>
<thead>
<tr>
<th>Grading</th>
<th>Symptom evaluation</th>
<th>Assessment</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild</td>
<td>≤5x ULN amylase and/or ≤5x ULN lipase</td>
<td>Consider abdominal CT with contrast Consider magnetic resonance cholangiopancreatography</td>
<td>Without evidence of pancreatitis: continue ICI</td>
</tr>
<tr>
<td>Moderate</td>
<td>≥3-5x ULN amylase and/or &gt;3x ULN lipase</td>
<td>Consider abdominal CT with contrast Consider magnetic resonance cholangiopancreatography Consider other causes of of elevated lipase/amylase</td>
<td>Without evidence of pancreatitis: continue ICI</td>
</tr>
<tr>
<td>Severe</td>
<td>≥5x ULN amylase and/or &gt;5x ULN lipase</td>
<td>Consider abdominal CT with contrast Consider magnetic resonance cholangiopancreatography Consider other causes of of elevated lipase/amylase</td>
<td>Without evidence of pancreatitis: continue ICI</td>
</tr>
</tbody>
</table>

Note: This table has been modified from NCCN and ESMO guidelines.

and persistent-severe epigastric pain, epigastric pain radiating to the back, elevations of serum lipase/amylase to ≥ 3 fold the upper limit of normal and also characteristic imaging findings of acute pancreatitis. Immunosuppression with corticosteroids should be used in cases with pancreatitis. Table 5 shows the pancreatic adverse events associated with ICIs, symptom evaluations, assessments and management.

In conclusion GI side effects are common in cases treated by ICIs and patients must be monitored with liver function tests and diarrhea and colitis must be monitored. Low grade toxicities may be treated by symptomatic measures but higher-grade toxicities requires interruption/cessation of the ICI and immunosuppressive drugs according to the severity of toxicity.

Conflict-of-interest

There is no conflict of interest.

References


35. https://www.fda.gov/Drugs/default.htm


73. Harbour SN, Maynard CL, Zindl CL, Schoeb TR, Weaver CT (2015) Th17 cells give rise to Th1 cells that are required for the pathogenesis of colitis. *Proc Natl Acad Sci U S A* 112: 7061-7066. [Crossref]


